Stockreport

NeuroSense Announces Completion of PARADIGM Study Highlighting PrimeC's Significant Efficacy and Survival Benefits in ALS [Yahoo! Finance]

NeuroSense Therapeutics Ltd.  (NRSN) 
PDF progression was slowed by 33% (p=0.007), demonstrated in a 58% improvement in survival rates Consistent data across subgroups underscore the potential of PrimeC to red [Read more]